The neuropharmacological substrates of nicotine reward: Reinforcing versus reinforcement-enhancing effects of nicotine

Behavioural Pharmacology

Volumn 20, Issue 3, 2009, Pages 211-225

  Paterson, Neil E ^a  

^a PSYCHOGENICS INC   (United States)

Author keywords

Dopamine; Gamma aminobutyric acid; Glutamate; Nicotine; Nicotinic acetylcholine receptors; Reinforcement enhancing; Reinforcing; Reward

Indexed keywords

18 METHOXYCORONARIDINE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMFEBUTAMONE; BACLOFEN; BHF 177; CGP 44532; DOPAMINE; DOPAMINE RECEPTOR; GLUTAMIC ACID; MECAMYLAMINE; MEMANTINE; METHYLLYCACONITINE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NICOTINE; NICOTINIC RECEPTOR; PICROTOXIN; UNCLASSIFIED DRUG; VARENICLINE;

BRAIN REGION; DRUG RECEPTOR BINDING; HUMAN; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; RECEPTOR BINDING; REINFORCEMENT; REVIEW; REWARD; SELF STIMULATION; SIGNAL TRANSDUCTION; SMOKING CESSATION; TOBACCO DEPENDENCE; VALIDITY; VISUAL STIMULATION;

ANIMALS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; NEUROPSYCHOLOGICAL TESTS; NICOTINE; NICOTINIC AGONISTS; REINFORCEMENT (PSYCHOLOGY); REWARD; TOBACCO USE DISORDER;

EID: 67649544402     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32832c7083     Document Type: Review

References (205)

1. Alkondon M, Albuquerque EX (2005). Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensltlzatlon and early in vivo functional up-regulation by nicotine and to block by bupropion. J Pharmacol Exp Ther 313:740-750.
2. Alkondon M, Pereira EF, Wonnacott S, Albuquerque EX (1992). Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Mol. Pharmacol 41:802-808.
3. Alkondon M, Braga MF, Perlera EF, Maelicke A, Albuquerque EX (2000). Alpha7 nicotinic acetylcholine receptors and modulation of GABA-ergic synaptic transmission in the hippocampus. Eur J Pharmacol 393:59-67.
4. 3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28: 1272-1280.
5. Arnold JM, Roberts DCS (1997). A critique of fixed and progressive-ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57:441-447.
6. Ashby CR Jr, Rohatgi R, Ngosuwan J, Borda T, Gerasimov MR, Morgan AE, et al. (1999). Implication of the GABA(B) receptor in gamma vinyl-GABA's inhibition of cocaine-induced increases in nucleus accumbens dopamine. Synapse 31:151-153.
7. Barik J, Wonnacott S (2006). Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol. Pharmacol 69:618-628.
8. Bauco P, Wise RA (1994). Potentiation of lateral hypothalamic and midline mesencephalic brain stimulation reinforcement by nicotine: examination of repeated treatment. J Pharmacol Exp Ther 271:294-301.
9. Benowitz NL (2008). Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 83:531-541.
10. Benwell ME, Balfour DJ, Birrell CE (1995). Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br J Pharmacol 114:454-460.
11. Benwell MEM, Balfour DJK (1997). Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur J Pharmacol 325:13-20.
12. Bespalov A, Dravolina O, Belozertseva I, Adamcio B, Zvartau E (2006). Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists. Behav Pharmacol 17:295-302.
13. Besson M, David V, Suarez S, Cormier A, Cazala P, Changeux J-P, Granon S (2006). Genetic dissociation of two behaviors associated with nicotine addiction: beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome. Psychopharmacology 187:189-199.
14. Blokhina EA, Kashkin VA, Zvartau EE, Danysz W, Bespalov AY (2005). Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacol 15:219-225.
15. C receptors. Trends Neurosci 18: 515-519.
16. Bozarth MA, Pudiak CM, KuoLee R (1998). Effect of chronic nicotine on brain stimulation reward. I. Effect of dally injections. Behav Brain Res 96:185-188.
17. Bruijnzeel AW, Markou A (2003). Effects of bupropion on responding for nicotine and food under fixed-ratio and progressive-ratio schedules of reinforcement in rats. Synapse 50:20-28.
18. Bruijnzeel AW, Markou A (2004). Adaptations in cholinergic transmission in the ventral tegmental area associated with the affective signs of nicotine withdrawal in rats. Neuropharmacology 47:572-579.
19. 2-like, receptor antagonism in the posterior hypothalamic region/anterior ventral tegmental area on brain reward function during chronic exposure to nicotine in rats. Brain Res 1058:91-100.
20. Buisson B, Bertrand D (2002). Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 23:130-136.
21. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, et al. (2001). Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 70:515-530.
22. Cagniard B, Beeler JA, Britt JP, McGehee DS, Marinelli M, Zhuang X (2006). Dopamine scales performance in the absence of new learning. Neuron 51:541-547.
23. Caine SB, Koob GF (1995). Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav Pharmacol 6:333-347.
24. Caine SB, Negus SS, Mello NK, Bergman J (1999). Effects of D1-like and D2-like agonists in rats that self-administer cocaine. J Pharmacol Exp Ther 291:353-360.
25. Carlezon WA Jr, Chartoff EH (2007). Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2: 2987-2995.
26. Carlezon WA Jr, Wise RA (1996). Microinjections of phencyclidlne and related drugs into the nucleus accumbens shell potentiate medial forebrain bundle brain stimulation reward. Psychopharmacol 128:413-420.
27. Champtiaux N, Gotti C, Cordera-Erausquln M, David DJ, Przybylski C, Lena C, et al. (2003). Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23:7820-7829.
28. Chaudhri N, Caggiula AR, Donny EC, Palmatier M, Liu X, Sved AF (2006). Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology 184:353-366.
29. Cheer JF, Heien ML, Garris PA, Carelli RM, Wightman RM (2005). Simultaneous dopamine and single-unit recordings reveal accumbens GABAergic responses: Implications for intracranial self-stimulation. Proc Natl Acad Sci USA 102:19150-19155.
30. Chen J, Nakamura M, Kawamura T, Takahashi T, Nakahara D (2006). Roles of pedunculopontine tegmental cholinergic receptors in brain stimulation reward in the rat. Psychopharmacology 184:514-522
31. Chiamulera C (2005). Cue reactivity in nicotine and tobacco dependence: a multiple-action model of nicotine as a primary reinforcement and as an enhancer of the effects of smoking-associated stimuli. Brain Res Brain Res Rev 48:74-97.
32. Clarke PB, Kumar R (1984). Effects of nicotine and d-amphetamine on intracranial self-stimulation in a shuttle box test in rats. Psychopharmacology 84:109-114.
33. 2-like dopamine receptor stimulation in rats. Psychopharmacology 182:65-74.
34. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002). SR141716, a central cannabinold [CB(1)] receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13: 451-463.
35. Corrigall WA, Coen KM (1989). Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 99:473-478.
36. Corrigall WA, Coen KM (1991). Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104:171-176.
37. Corrigall WA, Franklin KBJ, Coen KM, Clarke PBS (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285-289.
38. Corrigall WA, Coen KM, Adamson KL (1994). Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653:278-284.
39. Corrigall WA, Coen KM, Adamson KL, Chow BLC, Zhang J (2000). Response of nicotine self-administration in the rat to manipulations of μ-opioid and γ-amlnobutyric acid receptors in the ventral tegmental area. Psychopharmacology 149:107-114.
40. Corrigall WA, Coen KM, Zhang J, Adamson KL (2001). GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology 158:190-197.
41. Corrigall WA, Coen KM, Zhang J, Adamson L (2002). Pharmacological manipulations of the pedunculopontine tegmental nucleus in the rat reduce self-administration of both nicotine and cocaine. Psychopharmacology 160: 198-205.
42. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, et al. (2003). 3-[(2-methyl-1,3-thlazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206.
43. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003). Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat Psychopharmacology 168:347-358.
44. B receptor-positive modulator GS39783 (N,N′-dlcyclopentyl-2-methylsulfanyl- 5-nitro-pyrimidine4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 310:952-963.
45. Dallery J, Soto PL (2004). Herrnstein's hyperbolic matching equation and behavioral pharmacology: review and critique. Behav Pharmacol 15: 443-459.
46. Damsma G, Day J, Fibiger HC (1989). Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 168:363-368.
47. 1 receptors. Neuropharmacology 50:1030-1040.
48. Davies AR, Hardick DJ, Blagbrough IS, Potter BV, Wolstenholme AJ, Wonnacott S (1999). Characterisation of the binding of [3H]methyllycaconltine: a new radioligand for labeling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38:679-690.
49. DeNoble VJ, Mele PC (2006). Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonlum and naloxone. Psychopharmacology 184:266-272.
50. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner E, Ashby CR (1999). A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31:76-86.
51. B receptor agonist, is hedonically neutral and reduces cocaine-induced enhancement of reward. Neuropharmacology 42:626-632.
52. Donny EC, Caggiula AR, Mielke MM, Booth S, Gharib MA, Hoffman A, et al. (1999). Nicotine self-administration in rats on a progressive-ratio schedule of reinforcement. Psychopharmacology 147:135-142.
53. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006). of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CWS Drug Rev. 12:178-207.
54. Fattore L, Cossu G, Martellotta MC, Fratta W (2002). Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. A/c Alcoholism 37:495-498.
55. Feldman RS, Meyer JS, Quenzer LF (1997). Principles of Neuropsychopharmacology. Sunderland, MA: Sinauer Associates; pp. 249-276.
56. Fouriezos G, Wise RA (1976). Pimozlde-induced extinction of intracranial self-stimulation: response patterns rule out motor or performance deficits. Brain Res 103:377-380.
57. Fu Y, Matta SG, Sharp BM (1999). Local α-bungarotoxin-sensitive nicotinic receptors modulates hippocampal norepinephrine release by systemic nicotine. J Pharmacol Exp Ther 289:133-139.
58. Fu Y, Matta SG, Gao W, Brower VG, Sharp BM (2000). Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area. J Pharmacol Exp Ther 294:458-465.
59. Gallistel CR, Karras D (1984). Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol Biochem Behav 20: 73-77.
60. Garris PA, Kilpatrick M, Bunin MA, Michael D, Walker QD, Wightman RM (1999). Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation. Nature 398:67-69.
61. Gioanni Y, Rougeot C, Clarke PBS, Lepouse C, Thierry AM, Vidal C (1999). Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci 11:18-30.
62. Glick SD, Maisonneuve IM, Dickinson HA, Kitchen BA (2001). Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats. Eur J Pharmacol 422:87-90.
63. Glick SD, Maisonneuve IM, Kitchen BA (2002a). Modulation of nicotine self-administration in rats by combination therapy with agents blocking α3β4 nicotinic receptors. Eur J Pharmacol 448:185-191.
64. Glick SD, Maisonneuve IM, Kitchen BA (2002b). Antagonism of α3α4 nicotinic receptors as a strategy to reduce opioid and stimulant self-admlnistratlon. Eur J Pharmacol 438:99-105.
65. Goldberg SR, Spealman RD (1982). Maintenance and suppression of behavior by intravenous nicotine injections in squirrel monkeys. Fed Proc 41:216-220.
66. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47-55.
67. Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, Zoli M (2007). Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 74:1102-1111.
68. Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, Higgins GA (2000). Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294:1112-1119.
69. Harrison AA, Gasparini F, Markou A (2002). Nicotine potentiation of brain stimulation reward reversed by DHâE and SCH 23390, but not by eticlopride, LY314582 or MPEP in rats. Psychopharmacology 160:56-66.
70. Harvey SC, Luetje CW (1996). Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor β subunits. J Neurosci 16:3798-3806.
71. Harvey SC, Maddox FN, Luetje CW (1996). Multiple determinants of dihydro-β-erythroldine sensitivity on rat neuronal nicotinic receptor a subunits. J Neurochem 67:1953-1959.
72. Heimer L, Alheid GF (1991). Piecing together the puzzle of basal forebrain anatomy. In: Napier TC, Kalivas PW, Hanin I, editors. The basal forebrain: anatomy to function. New York, NY: Plenum Press; pp. 1-42.
73. Heimer L, Alheid GF, Zaborszky L (1985). The basal ganglia. In: Paxinos G, editor. The rat nervous system. Sydney, Australia: Academic Press; pp. 37-86.
74. Hernandez G, Hamdani S, Rajabi H, Conover K, Stewart J, Arvanitogiannis A, Shizgal P (2006). Prolonged rewarding stimulation of the rat medial forebrain bundle: neurochemical and behavioral consequences. Behav Neurosci 120:888-904.
75. Herrnsteln RJ (1970). On the law of effect. J Exp Anal Behav 13:243-266.
76. Hodos W (1961). Progressive ratio as a measure of reward strength. Science 134:943-944.
77. Huston-Lyons D, Kornetsky C (1992). Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol Biochem Behav 41:755-759.
78. Ikemoto S, Qin M, Zhu ZH (2006). Primary reinforcing effects of nicotine are triggered from multiple regions both inside and outside the ventral tegmental area. J Neurosci 26:723-730.
79. Imperato A, Mulas A, DiChiara G (1986). Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337-338.
80. Ivanova S, Greenshaw AJ (1997). Nicotine-induced decreases in ventral tegmental area electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron. Psychopharmacology 134:187-192.
81. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J Am Med Assoc 296:56-63.
82. Kanno T, Yaguchl T, Yamamoto S, Nagata T, Yamamoto H, Fujikawa H, Nishizaki T (2005). Bidirectional regulations for glutamate and GABA release in the hippocampus by alpha7 and non-alpha7 ACh receptors. Biochem Biophys Res Commun 338:742-747.
83. Karasawa J, Youshimizu T, CHaki S (2006). A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci Lett 393:127-130.
84. Kenny PJ, Markou A (2004). The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 25:265-272.
85. Kenny PJ, Markou A (2006). Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 31:1203-1211.
86. Kenny PJ, Gasparini F, Markou A (2003a). Group Il metabotropic and α-amino-3-hydroxy-5-methyl-4-lsoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306:1068-1076.
87. Kenny PJ, Paterson NE, Boutrel B, Semenova S, Harrison AA, Gasparlni F, et al. (2003b). Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci 1003:415-418.
88. Kenny PJ, Boutrel BJ, Gasparini F, Koob GF, Markou A (2005). Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology 179:247-254.
89. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF (2006). Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 26:5894-5900.
90. Kenny PJ, Chartoff E, Roberto M, Carlezon WA Jr, Markou A (2009). NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 34:266-281.
91. Kew JN, Kemp JA (2006). Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179:4-29.
92. Killeen PR, Posadas-Sanchez D, Johansen EB, Thrailkill EA (2009). Progressive ratio schedules of reinforcement. J Exp Psychol Anim Behav Process 35:35-50.
93. Klink R, de Kerchove d'Exaerde A, Zoll M, Changeux JP (2001). Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21:1452-1463.
94. Klitenick MA, DeWitte P and Kalivas PW (1992). Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J Neurosci 12:2623-2632.
95. Kofman O, McGlynn SM, Olmstead MC, Yeomans JS (1990). Differential effects of atropine, procaine and dopamine in the rat ventral tegmentum on lateral hypothalamic rewarding brain stimulation. Behav Brain Res 38:55-68.
96. Kornetsky C, Esposito RU (1979). Euphorigenic drugs: effects on the reward pathways of the brain. Federation Proc 38:2473-2476.
97. Kushner SA, Dewey SL, Kornetsky C. (1997). Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology 133:383-388.
98. Lança AJ, Adamson KL, Coen KM, Chow BL, Corrigall WA (2000). The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study. Neuroscience 96:735-742.
99. Lassen MB, Brown JE, Stobbs SH, Gunderson SH, Maes L, Valenzuela CF, et al. (2007). Brain stimulation reward Is integrated by a network of electrically coupled GABA neurons. Brain Res 1156:46-58.
100. 3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49:525-541.
101. Lecca D, Cacciapaglia F, Valentini V, Gronli J, Spiga S, Di Chiara G (2006). Preferential increase of extracellular dopamine in the rat nucleus accumbens shell as compared to that in the core during acquisition and maintenance of intravenous nicotine self-administration. Psychopharmacology 184:435-446.
102. Lena C, Changeux JP (1997). Role of Ca2 + ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci 17:576-585.
103. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA (2007). Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6:746-762.
104. LeSage MG, Keyler DE, Collins G, Pentel PR (2003). Effects of continuous nicotine Infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology 170:278-286.
105. Lesage MG, Shelley D, Ross JT, Carroll Fl, Corrigall WA (2009). Effects of the nicotinic receptor partial agonists varenlcllne and cytislne on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 91:461-467.
106. Li S X-M, Perry KW, Wong DT (2002). Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentration in three mesocorticolimblc areas of rats. Neuropharmacology 42:181-190.
107. Liechti ME, Markou A (2007a). Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur J Pharmacol 554:164-174.
108. Liechti ME, Markou A (2007b). Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochem Pharmacol 74:1299-1307.
109. Liechti ME, Lhiulller L, Kaupmann K, Markou A (2007). Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 27:9077-9085.
110. Liu X, Palmatier Ml, Caggiula AR, Donny EC, Sved AF (2007). Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats. Psychopharmacology 194:463-473.
111. Liu X, Caggiula AR, Palmatier Ml, Donny EC, Sved AF (2008). Cue-induced reinstatement of nicotine-seeking behaviour in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose. Psychopharmacology 196:365-375.
112. Macey DJ, Froestl W, Koob GF, Markou A (2001). Both GABA(B) receptor agonist and antagonists decreased brain stimulation reward in the rat. Neuropharmacology 40:676-685.
113. Mansvelder HD, Keath JR, MoGehee DS (2002). Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33:906-919.
114. Markou A, Koob GF (1992). Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51:111-119.
115. Markou A, Paterson NE (2001). The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-admlnistratlon and nicotine withdrawal in the rat. Nicotine Tob Res 3:361-373.
116. Markou A, Paterson NE (2009). Multiple motivational forces contribute to nicotine dependence. In: Caggiula AR, Bevins R, editors. The motivational impact of nicotine and its role in tobacco use. Nebr Symp Motiv. Berlin: Springer; pp. 65-89.
117. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux J-P, et al. (2005). Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436:103-107.
118. Miller DK, Sumithran SP, Dwoskin LP (2002). Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]noreplnephrine. J Pharmacol Exp Ther 302:1113-1122.
119. Mugnaini M, Tessari M, Tarter G, Merlo Pich E, Chiamulera C, Bunnemann B (2002). Upregulation of [3H]methyllycaconitine binding sites following continuous infusion of nicotine, without changes of α7 or α6 subunit mRNA: an autoradiography and in situ hybridization study in rat brain. Eur J Neurosci 16:1633-1646.
120. Nakahara D, Ozaki N, Kapoor V, Nagatsu T (1989). The effect of uptake inhibition on dopamine release from the nucleus accumbens of rats during self- or forced stimulation of the medial forebrain bundle: a microdialysis study. Neurosci Lett 104:136-140.
121. Nakahara D, Fuohlkarni K, Ozaki N, Iwasakl T, Nagatsu T (1992). Differential effect of self-stimulation on dopamine release and metabolism in the rat medial frontal cortex, nucleus accumbens and striatum studied by in vivo microdialysis. Brain Res 574:164-170.
122. Nakahara D, Ishida Y, Nakamura M, Furuno N, Nishimori T (2001). Intracranial self-stimulation induces Fos expression in GABA-ergic neurons in the rat mesopontine tegmentum. Neuroscience 106:633-641.
123. Nisell M, Nomikos GG, Svensson TH (1994a). Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16:36-44.
124. Nisell M, Nomikos GG, Svensson TH (1994b). Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 75:348-352.
125. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1989). Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2:273-279.
126. Oakman SA, Faris PL, Kerr PE, Cozzari C, Hartman BK (1995). Distribution of pontomesencephalic cholinergic neurons projecting to substantia nigra differs significantly from those projecting to ventral tegmental area. J Neurosci 15:5859-5869.
127. Omelchenko N, Sesack SR (2006). Cholinergic axons in the rat ventral tegmental area synapse preferentially onto mesoaccumbens dopamine neurons. J Comp Neurol 494:863-875.
128. Olds ME (1956). A preliminary mapping of electrical reinforcing effects in the rat brain. J Comp Physiol Psychol 49:281-285.
129. Olds ME (1996). Dopaminergic basis for the facilitation of brain stimulation reward by the NMDA receptor antagonist, MK-801. Eur J Pharmacol 306:23-32.
130. Olds ME, Domino EF (1969). Comparison of muscarinic and nicotinic cholinergic agonists on self-stimulation behavior. J Pharmacol Exp Ther 166:189-204.
131. 3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 9:585-602.
132. Palmatier Ml, Evans-Martin FF, Hoffman A, Cagglula AR, Chaudhrl N, Donny EC, et al. (2006). Dissociating the primary reinforcing and reinforcement-enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental relnforcers. Psychopharmacology 184:391-400.
133. Palmatier Ml, Liu X, Caggiula AR, Donny EC, Sved AF (2007a). The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine. Neuropsychopharmacology 32:1098-1108.
134. Palmatier Ml, Liu X, Donny EC, Caggiula AR, Sved AF (2007b). Metabotropic glutamate 5 receptor (mGluRS) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine. Neuropsychopharmacology 33:2139-2147.
135. Panagis G, Kastellakis A (2002). The effects of ventral tegmental administration of GABA(A), GABA(B), NMDA and AMPA receptor agonists on ventral pallidum self-stimulation. Behav Brain Res 131:116-123.
136. Panagis G, Spyraki C (1996). Neuropharmacological evidence for the role of dopamine in ventral pallidum self-stimulation. Psychopharmacology 123:280-288.
137. Panagis G, Kastellakis A, Spyraki C, Nomikos G (2000). Effects of methyllycaconitine (MLA), an α7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology 149:388-396.
138. Parker SL, Fu Y, McAllen K, Luo J, McIntosh JM, Lindstrom JM, Sharp BM (2004). Up-regulation of brain nicotinic acetylcholine receptors in the rat during longterm self-administration of nicotine: disproportionate increase of the α6 subunit. Mol Pharmacol 65:611-622.
139. Paterson NE (2009). Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol 603:1-11.
140. Paterson NE, Markou A (2002). Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat. Synapse 44:252-253.
141. Paterson NE, Markou A (2005). The mGlu5 antagonist MPEP decreased break-points for nicotine, cocaine and food. Psychopharmacology 179: 255-261.
142. Paterson NE, Markou A (2007). Design of animal models and treatments for addiction and depression co-morbidity. Neurotoxicity Res 11:1-32.
143. Paterson NE, Semenova S, Gasparlni F, Markou A (2003). The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology 167:257-264.
144. 8 receptor agonists baclofen and CGP44532 decrease nicotine self-administration in the rat. Psychopharmacology 172:179-186.
145. B receptormediated regulation of brain reward function. Neuropharmacology 49: 953-962.
146. Paterson NE, Froestl W, Markou A (2005b). Repeated administration of the GABA(B) receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-Induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology 30:119-128.
147. Paterson NE, Balfour DJ, Markou A (2007). Chronic bupropion attenuated nicotine withdrawal, measured by brain reward function and somatic signs, via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25:3099-3108.
148. Paterson NE, Balfour DJ, Markou A (2008a). Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nic Tobacco Res 10:995-1008.
149. Paterson NE, Semenova S, Markou A (2008b). Chronic, but not acute, desipramine attenuated nicotine withdrawal and decreased nicotine self-administration in the rat. Psychopharmacology 198:351-362.
150. B Receptors Decreased Nicotine Self-administration and Counteracted Nicotine-induced Facilitation of Brain Reward Function in Rats. J Pharmacol Exp Ther 326:306-314.
151. Phillips AG, Blaha CD, Fibiger HC (1989). Neurochemical correlates of brainstimulation reward measured by ex vivo and in vivo analyses. Neurosci Biobehav Rev 13:99-104.
152. Picciotto MR, Zoli M, Rimondinl R, Lena C, Marubio LM, Pich EM, et al. (1998). Acetylcholine receptors containing the ß2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177.
153. Pradhan SN, Bowling C (1971). Effects of nicotine on self-stimulation in rats. J Pharmacol Exp Ther 176:229-243.
154. Rada PV, Mark GP, Hoebel BG (1998). Dopamine release in the nucleus accumbens by hypothalamic stimulation-escape behavior. Brain Res 782:228-234.
155. Rada PV, Mark GP, Yeomans JJ, Hoebel BG (2000). Acetylcholine release in ventral tegmental area by hypothalamic self-stimulation, eating, and drinking. Pharmacol Biochem Behav 65:375-379.
156. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG (2001). The N-methyl-D-aspartate receptor channel blockers memantine. MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured
157. Rauhut AS, Dwoskin LP, Bardo MT (2002). Reboxetine: attenuation of nicotine self-administration in rats. J Pharmacol Exp Ther 303:664-672.
158. Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT (2003). Effect of bupropion on nicotine self-admlnistratlon in rats. Psychopharmacology 169:1-9.
159. Rauhut AS, Dwoskin LP, Bardo MT (2005). Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res 7:901-907.
160. Raybuck JD, Portugal GS, Lerman C, Gould TJ (2008). Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci 122:1166-1171.
161. Redish AD (2004). Addiction as a computational process gone awry. Science 306:1944-1947.
162. Reld MS, Fox L, Ho LB, Berger SP (2000). Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization. Synapse 35:129-136.
163. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007a). Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316-325.
164. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. (2007b). Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994.
165. Rose JE (2006). Nicotine and non-nicotine factors in cigarette addiction. Psychopharmacology 184:274-285.
166. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV (1994). Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56:86-99.
167. 3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 559:173-179.
168. Rossetti ZL, Marcangione C, Wise RA (1998). Increase of extracellular glutamate and expression of Fos-like immunoreactlvity in the ventral tegmental area in response to electrical stimulation of the prefrontal cortex. J Neurochem 70:1503-1512.
169. Salamone JD, Correa M (2002). Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3-25.
170. Sohilstrom B, Nomikos GG, Nisell M, Hertel P, Svensson TH (1998a). N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82:781-789.
171. Schilstrom B, Svensson HM, Svensson TH, Nomikos GG (1998b). Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of α7 nicotinic receptors in the ventral tegmental area. Neuroscience 85:1005-1009.
172. Sesack SR, Pickel VM (1992). Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 320:145-160.
173. Shoaib M (2007). The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behavior in rats. Neuropharmacology 54:438-444.
174. Shoaib M, Schindler CW, Goldberg SR (1997). Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology 129:35-43.
175. B agonist baclofen modifies cocaine self-administration in rats. Behav Pharmacol 9:195-206.
176. Shoaib M, Sidhpura N, Shafait S (2002). Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology 165:405-412.
177. Singh J, Desiraju T, Raju JR (1997). Dopamine receptor sub-types involvement in nucleus accumbens and ventral tegmentum but not in medial prefrontal cortex: on self-stimulation of lateral hypothalamus and ventral mesencephalon. Behav Brain Res 86:171-179.
178. Skinner BF (1953). Science and human behavior. New York, NY: Macmillan.
179. B receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology 30:2065-2072.
180. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, Tricklebank M (2007). Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology 190:157-170.
181. Stafford D, LeSage MG, Glowa JR (1998). Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology 139:169-184.
182. Steffensen SC, Lee RS, STobbs SH, Henriksen SJ (2001). Responses of ventral tegmental area GABA neurons to brain stimulation reward. Brain Res 906:190-197.
183. Sziraki I, Sershen H, Benuok M, Hashim A, Lajtha A (1998). Receptor systems participating in nicotine-specific effects. Neurochem Int 33:445-457.
184. Sziraki I, Sershen H, Hashim A, Lajtha A (2002). Receptors in the ventral tegmental area mediating nicotine-induced dopamine release in the nucleus accumbens. Neurochem Res 27:253-261.
185. Tessari M, Pilla M, Andreoli M, Hutoheson DM, Heidbreder CA (2004). Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 499:121-133.
186. Tobler PN, Fiorillo CD, Schultz W (2005). Adaptive coding of reward value by dopamine neurons. Science 307:1642-1645.
187. Tzschentke TM, Schmidt WJ (1999). Memantine does not substantially affect brain stimulation reward: comparison with MK-801. Brain Res 845: 192-198.
188. Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, et al. (2001). Positive allosteric modulation of native and recombinant gammaaminobutyrlc acid (B) receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2- dimethylpropyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 60:963-971.
189. Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, et al. (2003). N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidlne-4,6- diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyrlc acidB receptor function. J Pharmacol Exp Ther 307:322-330.
190. Vidal C, Changeux JP (1993). Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 56:23-32.
191. Villegier A-S, Loftipour S, Belluzzi JD, Leslie FM (2007). Involvement of alpha-1 adrenergic receptors in tranylcyproimne enhancement of nicotine self-administration in rat. Psychopharmacology 193:457-465.
192. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 22:9595-9603.
193. Watkins SS, Epping-Jordan MP, Koob GF, Markou A (1999). Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62:743-751.
194. Westerink BH, Kwint HF and deVries JB (1996). The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16:2605-2611.
195. Willick ML, Kokkinidis L (1995). The effects of ventral tegmental administration of GABAA, GABAB and NMDA receptor agonists on medial forebrain bundle self-stimulation. Behav Brain Res 70:31-36.
196. Wise R, Marcangione C, Bauco P (1998). Blockade of the reward-potentiating effects of nicotine on lateral hypothalamic brain stimulation by chlorisondamine. Synapse 29:72-79.
197. Xi ZX, Stein EA (1999). Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J Pharmacol Exp Ther 290:1369-1374.
198. Yao WD, Spealman RD, Zhang J (2008). Dopaminergic signaling in dendritic spines. Biochem Pharmacol 75:2055-2069.
199. Yeomans J, Baptista M (1997). Both nicotinic and muscarinic receptors in ventral tegmental area contribute to brain-stimulation reward. Pharmacol Biochem Behav 57:915-921.
200. Yeomans JS, Kofman O, McFarlane V (1985). Cholinergic involvement in lateral hypothalamic rewarding brain stimulation. Brain Res 329:19-26.
201. Yeomans JS, Mathur A, Tampakeras M (1993). Rewarding brain stimulation: role of tegmental cholinergic neurons that activate dopamine neurons. Behav Neurosci 107:1077-1087.
202. You ZB, Tzschentke TM, Brodin E, Wise RA (1998). Electrical stimulation of the prefrontal cortex increases cholecystokinin, glutamate, and dopamine release in the nucleus accumbens: an in vivo microdialysis study in freely moving rats. J Neurosci 18:6492-6500.
203. You ZB, Chen YQ, Wise RA (2001). Dopamine and glutamate release in the nucleus accumbens and ventral tegmental area of rat following lateral hypothalamic self-stimulation. Neuroscience 107:629-639.
204. Zarevics P, Setler PE (1979). Simultaneous rate-independent and rate-dependent assessment of intracranial self-stimulation: evidence for the direct involvement of dopamine in brain reinforcement mechanisms. Brain Res 169:499-512.
205. Zarevics P, Setler PE (1981). Effects of GABAergic drugs on brain stimulation reward as assessed by a threshold method. Brain Res 215:201-209.